2025.11.17
CD34+ cells-dubbed the "seed cells" of the human hematopoietic system-are vital hematopoietic stem/progenitor cells (HSCs/HPCs) defined by surface CD34 glycoprotein expression. Beyond their core abilities of self-renewal (sustaining a stable cell pool) and multipotent differentiation into all blood lineages, these cells are clinical workhorses: sourced from bone marrow, mobilized peripheral blood, or umbilical cord blood, they are enriched via flow cytometry and directly influence hematopoietic stem cell transplantation success. Their robust in vitro expansion also makes them indispensable for treating hematological diseases, underscoring the need for reliable cryopreservation that preserves viability and function.
Enter Kryogene™ Cell Freezing Media - CGT: an FDA Master File-compliant solution tailored to the unique demands of cell and gene therapy (CGT) drugs. Unlike generic cryopreservation media, it’s engineered to shield high-value cells from freeze-thaw damage, ensuring optimal viability, functionality, and consistency throughout storage and recovery-critical for CGT’s rigorous clinical standards. Safe, efficient, and user-friendly, it’s designed to support the full potential of therapeutic cells like CD34+.
Our head-to-head study against a globally renowned cryopreservation brand-one with a proven track record supporting the approval and launch of numerous cell therapy products-proves Kryogene™’s superiority: We isolated hCD34+ cells from mobilized peripheral blood (Donor 1) and umbilical cord blood (Donors 2 & 3), cryopreserving them in Kryogene™ Cell Freezing Media - CGT or the competitor for 3 months. Post-thaw, cells were cultured with commercial expansion kits, and results spoke volumes: Key time points (Day 7 and 13) revealed significantly higher total nucleated cell (TNC) expansion multiples with Kryogene™. Flow cytometry further confirmed enhanced expansion of functional HSPC subsets-CD34+, High CD34+, and CD34+/CD90+-the very populations driving effective hematopoietic reconstitution. Notably, post-thaw viability exceeded 90% across all donor samples, with no significant changes in CD34+ surface marker expression-validating that Kryogene™ preserves the phenotypic integrity of these critical therapeutic cells.
For CGT researchers and clinicians seeking to protect CD34+ cell potency-even against industry-leading alternatives - Kryogene™ Cell Freezing Media - CGT is the trusted choice. Preserve what matters most-choose excellence in cryopreservation.
